MedPath

Effect of levetiracetam and topiramate in infantile spasms

Phase 2
Recruiting
Conditions
Infantile spasms.
Other generalized epilepsy and epileptic syndromes
Registration Number
IRCT20091027002639N21
Lead Sponsor
Yazd University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Age range of 2 months-1 year
Having infantile spasms based on definition of the International League Against Epilepsy
Resistance of their seizure to treatment of 2 mg/kg/day prednisolone for two months
Not used of other antiepileptic drugs

Exclusion Criteria

Discontinuation of levetiracetam and topiramate usage for more than one week
Allergy to levetiracetam and topiramate
Irregular drugs usage
Not returning for follow up

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Daily frequency of seizure. Timepoint: Before and after three months of treatment. Method of measurement: Asking from patient parents.;Treatment response. Timepoint: Before and after three months of treatment. Method of measurement: Asking from patient parents.
Secondary Outcome Measures
NameTimeMethod
Frequency of more than 50 % of reduction in daily frequency of seizure. Timepoint: Before and three months after treatment. Method of measurement: Asking from parents of patient.;Clinical side effects. Timepoint: During three months of treatment. Method of measurement: Asking from parents of patient.
© Copyright 2025. All Rights Reserved by MedPath